Executive Summary

Project Transfidelity focuses on preventing neurodegenerative diseases by improving the accuracy of protein synthesis, thereby reducing the formation of harmful protein aggregates. This approach targets the root cause of these diseases, aiming to provide a novel treatment strategy that goes beyond symptom management.

The proposed research is presented here at this link.

VitaDAO has done a preliminary assessment of this project as well toward dedicating $50,000 of investment - that assessment and discussion is linked herein. The Problem and Solution sections below are extracted from the VDP-152 proposal.

The full CDP-8 Proposal is available at this link.

This CDP-8 proposal is to authorize Cerebrum investing $50k USD in funding from for the Transfidelity project on the Molecule Catalyst Platform.

Project Trans-Fidelity Assessment

Translational fidelity as a mechanistic aspect of aging and disease is an attractive, and still very competitive starting point for drug discovery and development. There are risks and benefits. As drugs would target general mechanisms, they may lack specificity and lead to adverse events and/or lack efficacy. The field is also relatively young and as most companies in the CNS therapeutic area focus on very defined pathophysiology (e.g. amyloids and α-synuclein aggregates in respectively Alzheimer’s Dementia and Parkinson’s Disease) this field may be very attractive to pioneer in.

Some of the data as presented is of high quality but would need due diligence and further discussion with the scientists.

Pros

• Solid science,
• proof of principle,
• excellent scientific infrastructure in both universities,
• top scientists involved,
• this may have much wider implications than just neurodegeneration, and
• strategic value for Cerebrum DAO to begin new collaborations with local Swiss Universities on research related to its mission.

Cons

• the chemistry is very immature, and
• the approaches need to be very well designed and controlled to create drug-like molecules.

Senior Reviews

Cerebrum completed three assessments with Senior Reviewers in neuroscience and drug development. Below are links to their assessments, which all are consistent with the conclusions written in this recommendation which support (a) a modest capital commitment at this stage from Cerebrum and (b) support from Cerebrum to ensure the research being conducted under this funding is designed with translation to therapeutic potential in mind from the start.

• Senior Review 1

• Senior Review 2

• Senior Review 3

Conclusion

It’s a relatively early project that still requires significant work to reach a true proof of concept, in research terms.

Yet, the field is relatively young and specifically in the field of translational fidelity the competition seems small as compared to other fields, specifically for neurodegenerative diseases. This may be a good time to step in and also assist in some of the crucial decisions to be made.

Passing CDP-8 will authorize Cerebrum to make a $50,000 investment in Intellectual Property Tokens (IPTs) on the Molecule Catalyst platform, and assign a Deal Squad to have active involvement in collaborating with the Principle Investigators to advance this research toward the clinic.